Demonstrates a protein signature predicting biochemical recurrence in intermediate-risk prostate cancer patients, suggesting improved personalized treatment.
This study demonstrates the ability of a protein-based signature to risk-stratify prostate cancer patients with Gleason grade groups 2 and 3 and predict the risk of biochemical recurrence.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: